摘要
目的探讨黄皮酰胺(Clausenamide,Clau)对糖尿病大鼠海马血红素加氧酶1和2(HO-1和HO-2)表达的影响。方法♂Wistar大鼠腹腔注射链脲佐菌素(48mg·kg-1)建立糖尿病模型,给予不同药物治疗3mon后,分别以RT-PCR法和免疫组织化学法观察大鼠海马HO-1和HO-2 mR-NA和蛋白质的表达。结果①RT-PCR结果显示,糖尿病大鼠海马的HO-1和HO-2 mRNA表达水平明显增加(P<0.01);而Clau(50,25mg·kg-1)治疗组大鼠海马的HO-1和HO-2 mRNA的表达水平明显降低(P<0.01),表明Clau可明显抑制糖尿病大鼠海马HO-1和HO-2 mRNA的表达水平;②免疫组化结果表明,糖尿病大鼠海马HO-1和HO-2的蛋白质表达明显升高(P<0.01),表明HO-1和HO-2蛋白质的异常表达参与了糖尿病障碍的过程,而Clau通过抑制HO-1和HO-2的蛋白质表达对糖尿病大鼠起到保护作用的。结论黄皮酰胺可能通过抑制海马的HO-1和HO-2 mRNA及蛋白质表达起到糖尿病大鼠的海马保护作用的。
Aim To explore the effects of clausenamide (Clau) on hippocampal heme oxygenase (HO-1 and HO-2) expressions in diabetic rats. Methods The di- abetic rats model was produced by injecting streptozotocin (48mg·kg^-1). After 3 months, the HO-1 and HO-2 mRNA and protein expressions in hippocampus of diabetic rats were detected by RT-PCR and immunohistochemistry respectively. Results (1) The results of RT-PCR showed that the protein expressions of HO-1 and HO-2 mRNA in hippocampus of diabetic group were higher than those of control group ( P 〈 0. 01 ). The expressions of HO-1 and HO-2 mRNA of Clautreated group (50,25 mg·kg^-1) were lower those of diabetic group ( P 〈 0. 01 ). (2) The results of immunohistochemistry showed that the protein expressions of HO-1 and HO-2 in hippocampus of diabetic group were obviously increased ( P 〈 0. 01 ), but Clau could inhibit the expressions of HO-1 -and HO-2. Conclusion Clau can significantly inhibit HO-1 and HO-2 expressions in hippocampus,which may account for the protective effects.
出处
《中国药理学通报》
CAS
CSCD
北大核心
2008年第12期1663-1665,共3页
Chinese Pharmacological Bulletin
基金
广西壮族自治区硕士研究生科研创新项目资助课题(No2006105981007M10)
河南省教育厅资助课题(No2008B180012)
关键词
糖尿病
黄皮酰胺
海马
血红素加氧酶
diabetes mellitus
clausenamide
hippocampus
heme oxygenase